A Study of CAR-T Cells Targeting Autoimmune Diseases
Not Applicable
Not yet recruiting
- Conditions
- Autoimmune Diseases
- Interventions
- Drug: CAR-T
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT06661811
- Locations
- 🇨🇳
Beijing Gaobo Boren Hospital, Beijing, China
Efficacy and Safety of the Anti-COVID-19 Antibody SA55 for Injection in Patients With Hematological Disorders Who Are Persistently Positive for COVID-19
Not Applicable
Recruiting
- Conditions
- Hematological DisordersCOVID-19
- Interventions
- Biological: Anti-COVID-19 Antibody SA55 for Injection
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT05675943
- Locations
- 🇨🇳
Beijing Boren Hospital, Beijing, Beijing, China
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
Phase 1
Withdrawn
- Conditions
- T-Cell Acute Lymphoblastic Leukemia/Lymphoma
- Interventions
- Biological: CD5 CAR T (CT125B)
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT05487495
- Locations
- 🇨🇳
Beijing Gaobo Boren Hospital, Beijing, Beijing, China
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies
Phase 1
- Conditions
- Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
- Interventions
- Biological: CAR-NK-CD19 Cells
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT05410041
- Locations
- 🇨🇳
Beijing Boren Hospital, Beijing, Beijing, China
A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors
Early Phase 1
Terminated
- Conditions
- Relapsed/Refractory LymphomaAdvanced Solid Tumor
- Interventions
- Biological: OVV-01 Injection+IBR900 Cell Injection
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT05271279
- Locations
- 🇨🇳
Beijing Boren Hospital, Beijing, Beijing, China
Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
Phase 1
Withdrawn
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biological: CI-135 CAR-T cells (0.5 x 10^6 CAR-T+ cells/kg，1.0 x 10^6 CAR-T+ cells/kg)
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 7
- Registration Number
- NCT05266950
- Locations
- 🇨🇳
Beijing Gaobo Boren Hospital, Beijing, Beijing, China
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Phase 1
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biological: Dual CD33/CLL1 CAR T
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2022-02-21
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05248685
- Locations
- 🇨🇳
Beijing Boren Hospital, Beijing, Beijing, China
Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
Phase 1
Terminated
- Conditions
- T-Cell Acute Lymphoblastic Leukemia
- Interventions
- Biological: CD5 CART
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT05032599
- Locations
- 🇨🇳
Beijing Boren Hospital, Beijing, Beijing, China
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor
Phase 1
Terminated
- Conditions
- T Cell LymphomaT-cell Leukemia
- Interventions
- Drug: Efficacy of LCAR-T2C CAR-T cells
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT04973527
- Locations
- 🇨🇳
Beijing Boren Hospital, Beijing, Beijing, China
Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma
Phase 1
Completed
- Conditions
- T Cell LymphomaT-cell Leukemia
- Interventions
- Biological: chimeric antigen receptor T cell treatment
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT04840875
- Locations
- 🇨🇳
Beijing Boren Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath